NRSNW | tickerfilter.com

Fundamental analysis

Profitability 0%

Dept financing 0%

Liquidity 0%

Performance 10%

Performance

5 Days

12.51%

1 Month

28.21%

3 Months

68.82%

6 Months

-43.33%

1 Year

-31.73%

2 Year

-41.36%

Key data

Stock price

$0.17

P/E Ratio

0.00

DAY RANGE

N/A - N/A

EPS

$0.00

52 WEEK RANGE

$0.07 - $0.65

52 WEEK CHANGE

-$0.10

MARKET CAP

17.329 M

YIELD

N/A

SHARES OUTSTANDING

1.846 M

DIVIDEND

N/A

EX-DIVIDEND DATE

N/A

NEXT EARNINGS DATE

N/A

BETA

0.00

PUBLIC FLOAT

AVERAGE 10 VOLUME

$800

AVERAGE 30 VOLUME

$1,483

Company detail

CEO:
Region: US
Website: neurosense-tx.com
Employees: 18
IPO year: -

Issue type:
Market: XNAS
Industry: Research and Development in Biotechnology (except Nanobiotechnology)
Sector: Professional, Scientific, and Technical Services

advancing research, development and therapy for als. neurosense therapeutics is a biotech company focusing on the development of mirnas as a novel treatment for als. currently preparing for a first clinical study in patients in usa

NRSNW - NeuroSense Therapeutics Ltd - Warrants (09/11/2026)